ATE301676T1 - Antikörper gegen die ed-b domäne von fibronektin, solche antikörper enthaltende konjugate, und deren verwendung zur diagnose und therapie von angiogenese-assoziierten tumoren und krankheiten - Google Patents
Antikörper gegen die ed-b domäne von fibronektin, solche antikörper enthaltende konjugate, und deren verwendung zur diagnose und therapie von angiogenese-assoziierten tumoren und krankheitenInfo
- Publication number
- ATE301676T1 ATE301676T1 AT99923571T AT99923571T ATE301676T1 AT E301676 T1 ATE301676 T1 AT E301676T1 AT 99923571 T AT99923571 T AT 99923571T AT 99923571 T AT99923571 T AT 99923571T AT E301676 T1 ATE301676 T1 AT E301676T1
- Authority
- AT
- Austria
- Prior art keywords
- antibodies
- fibronectin
- angiogenesis
- domain
- relates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Optics & Photonics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7533898A | 1998-05-11 | 1998-05-11 | |
| US09/300,425 US20030045681A1 (en) | 1998-05-11 | 1999-04-28 | Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis |
| PCT/EP1999/003210 WO1999058570A2 (en) | 1998-05-11 | 1999-05-11 | Antibodies to the ed-b domain of fibronectin, conjugates containing them and use therefor for diagnosis and therapy of tumors and diseases associated with angiogenesis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE301676T1 true ATE301676T1 (de) | 2005-08-15 |
Family
ID=26756726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99923571T ATE301676T1 (de) | 1998-05-11 | 1999-05-11 | Antikörper gegen die ed-b domäne von fibronektin, solche antikörper enthaltende konjugate, und deren verwendung zur diagnose und therapie von angiogenese-assoziierten tumoren und krankheiten |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20070189963A1 (de) |
| EP (1) | EP1084145B1 (de) |
| JP (1) | JP2002514405A (de) |
| CN (1) | CN1250571C (de) |
| AT (1) | ATE301676T1 (de) |
| AU (1) | AU759207B2 (de) |
| BR (1) | BRPI9910394B8 (de) |
| CA (1) | CA2333833C (de) |
| CZ (1) | CZ300495B6 (de) |
| DE (1) | DE69926630T2 (de) |
| DK (1) | DK1084145T3 (de) |
| EA (1) | EA005685B1 (de) |
| EE (1) | EE05435B1 (de) |
| ES (1) | ES2247802T3 (de) |
| HU (1) | HU225675B1 (de) |
| IL (1) | IL139452A0 (de) |
| IS (1) | IS2522B (de) |
| NO (1) | NO327732B1 (de) |
| NZ (1) | NZ508600A (de) |
| PL (1) | PL199353B1 (de) |
| SK (1) | SK286822B6 (de) |
| TR (1) | TR200003317T2 (de) |
| TW (1) | TWI259837B (de) |
| WO (1) | WO1999058570A2 (de) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5965132A (en) | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
| US6749853B1 (en) | 1992-03-05 | 2004-06-15 | Board Of Regents, The University Of Texas System | Combined methods and compositions for coagulation and tumor treatment |
| GB9610967D0 (en) | 1996-05-24 | 1996-07-31 | Cambridge Antibody Tech | Specific binding members,materials and methods |
| US6773916B1 (en) | 1999-01-05 | 2004-08-10 | The Flinders University Of South Australia | Agents and methods for treatment and diagnosis of ocular disorders |
| DE19932688B4 (de) | 1999-07-13 | 2009-10-08 | Scil Proteins Gmbh | Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen |
| DE19947559A1 (de) * | 1999-09-24 | 2001-04-19 | Schering Ag | Antikörper-Farbstoffkonjugate gegen Zielstrukturen der Angiogenese zur intraoperativen Tumorranddarstellung |
| US6319273B1 (en) * | 1999-12-16 | 2001-11-20 | Light Sciences Corporation | Illuminating device for treating eye disease |
| ATE526039T1 (de) * | 2000-02-24 | 2011-10-15 | Philogen Spa | Zusammensetzungen und verfahren zur behandlung von angiogenese in pathologischen schädigungen |
| CA2400622A1 (en) | 2000-02-24 | 2001-08-30 | Eidgenossische Technische Hochschule Zurich | Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis |
| DE10045803A1 (de) * | 2000-09-07 | 2002-04-11 | Schering Ag | Rezeptor der EDb Fibronektin-Domäne |
| EP1381629B1 (de) * | 2000-09-07 | 2008-09-10 | Bayer Schering Pharma Aktiengesellschaft | REZEPTOR DER EDb-FIBRONEKTIN-DOMÄNE (II) |
| US20030100010A1 (en) * | 2001-11-23 | 2003-05-29 | George Jackowski | Fibrinogen biopolymer Marker predictive of type II diabetes |
| EP1453546A2 (de) * | 2001-12-04 | 2004-09-08 | Nanospectra Biosciences, Inc. | Behandlung von angiogenese-assoziierten erkrankungen mit gezielten nanopartikeln |
| RU2352582C2 (ru) * | 2002-01-03 | 2009-04-20 | Шеринг Акциенгезельшафт | Конъюгаты, содержащие антитело, специфическое для ed-в-домена фибронектина, и их применение для обнаружения и лечения опухолей |
| DE60333820D1 (de) * | 2002-01-03 | 2010-09-30 | Bayer Schering Pharma Ag | Konjugate mit einem für die ed-b-domäne von fibronectin spezifischen antikörper, und deren verwendung zum nachweis und zur behandlung von tumoren |
| AU2003219370B2 (en) * | 2002-03-11 | 2009-01-15 | Philogen S.P.A | Antibodies derived rom anti ED-B L19 and targeting tumor vasculature |
| EP2283868B1 (de) | 2002-07-15 | 2016-03-30 | Board of Regents, The University of Texas System | Peptide mit Bindung an Phosphatidylethanolamine und ihre Verwendung bei der Behandlung von Virusinfektionen und Krebs |
| DE10324447A1 (de) | 2003-05-28 | 2004-12-30 | Scil Proteins Gmbh | Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin |
| DE10348319A1 (de) * | 2003-10-17 | 2005-05-19 | Schering Ag | Bindemoleküle für die Extra-Domäne B von Fibronectin zur Detektion von atherosklerotischen Plaques |
| US7785591B2 (en) | 2004-10-14 | 2010-08-31 | Morphosys Ag | Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies |
| EP1957531B1 (de) * | 2005-11-07 | 2016-04-13 | Genentech, Inc. | Bindungspolypeptide mit diversifizierten und konsensus-vh/vl-hypervariablen sequenzen |
| CN101356271A (zh) * | 2005-11-09 | 2009-01-28 | 拜耳先灵医药股份有限公司 | 功能阻断性抗-ed-b-纤连蛋白抗体的鉴别与鉴定 |
| EP1842553A1 (de) | 2006-04-07 | 2007-10-10 | Bayer Schering Pharma Aktiengesellschaft | Kombination von einem Anti-EDb Fibronektin Domäne Antikörper/ IL2 Fusionsprotein und einem kleinen Molekül |
| EP1925664A1 (de) | 2006-11-15 | 2008-05-28 | Scil proteins GmbH | Künstliche Bindungsproteine auf Grundlage einer modifizierten alpha-Helix Region von Ubiquitin |
| ES2382058T3 (es) | 2008-01-17 | 2012-06-04 | Philogen S.P.A. | Combinación de una proteína de fusión de un anticuerpo dirigido contra el EDB de la fibronectina-IL-2, y una molécula de unión a los linfocitos B, progenitores de los linfocitos B y/o sus homólogos cancerosos |
| EP2100621A1 (de) | 2008-03-10 | 2009-09-16 | mivenion GmbH | Polyether-Polyol-Dendron-Konjugate mit Effektormolekülen für biologisches Targeting |
| JP2009244154A (ja) | 2008-03-31 | 2009-10-22 | Nationa Hospital Organization | 老化、および血管障害を伴う疾患の検定のための組成物、キットおよび方法 |
| EP2116555A1 (de) | 2008-05-08 | 2009-11-11 | Bayer Schering Pharma Aktiengesellschaft | Verwendung eines spezifisch an ED-B Fibronectin bindenden radioaktiv markierten Moleküls bei einem Verfahren zur Behandlung von Hodgkin-Lymphom |
| US20110306065A1 (en) * | 2008-11-12 | 2011-12-15 | The Trustees Of The University Of Pennsylvania | Use of an antibody and a rare-earth based crystal |
| RU2556820C2 (ru) | 2009-12-14 | 2015-07-20 | Сцил Протеинс Гмбх | Модифицированные убиквитиновые белки со специфической связывающей активностью для экстрадомена "в" фибронектина |
| WO2011110490A1 (en) | 2010-03-09 | 2011-09-15 | Bayer Pharma Aktiengesellschaft | Process for the production of radioactively labelled scfv antibody fragments, kits and compositions |
| WO2012171541A1 (en) | 2011-06-15 | 2012-12-20 | Scil Proteins Gmbh | Human fusion proteins comprising interferons and hetero-dimeric modified ubiquitin proteins |
| JP6146821B2 (ja) | 2011-06-15 | 2017-06-14 | ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ | 修飾ユビキチンに基づく二量体型結合タンパク質 |
| ES2657743T3 (es) | 2011-07-19 | 2018-03-06 | Philogen S.P.A. | Terapia secuencial con anti-CTLA-4 e IL-2 dirigida |
| RU2481839C2 (ru) * | 2011-08-16 | 2013-05-20 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Башкирский государственный медицинский университет Министерства здравоохранения и социального развития" | Способ лечения ишемической болезни сердца с дистальным или диффузным поражением коронарных артерий |
| WO2013186329A1 (en) | 2012-06-13 | 2013-12-19 | Scil Proteins Gmbh | Human fusion proteins comprising single chain tnfalpha and targeting domains |
| WO2014094799A1 (en) | 2012-12-19 | 2014-06-26 | Scil-Proteins-Gmbh | Ubiquitin moieties as a means for prolonging serum half-life |
| US10611830B2 (en) * | 2013-06-06 | 2020-04-07 | Hefei Lifeon Pharmaceutical Co. Ltd. | Human antibody against ED-B domain of fibronectin and uses thereof |
| JP6738340B2 (ja) | 2015-02-06 | 2020-08-12 | ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ | 新規なｅｇｆｒ結合タンパク質 |
| EP3322721B1 (de) | 2015-07-16 | 2021-12-08 | Navigo Proteins Gmbh | Von staphylococcus aureus protein a immunoglobulin bindende proteine |
| JP2018520675A (ja) | 2015-07-20 | 2018-08-02 | ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ | ジユビキチン変異タンパク質をベースとした新規結合タンパク質及びその生成方法 |
| US20180340936A1 (en) * | 2015-11-16 | 2018-11-29 | Hefei Lifeon Pharmaceutical Co. Ltd. | Use of ed-b protein in diagnosis of tissue hyperplasia |
| AU2017260274A1 (en) | 2016-05-04 | 2018-11-01 | Navigo Proteins Gmbh | Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker |
| GB201612317D0 (en) | 2016-07-15 | 2016-08-31 | Philogen Spa | Antibody compositions |
| JP6951417B2 (ja) | 2016-08-11 | 2021-10-20 | レプリゲン・コーポレイションＲｅｐｌｉｇｅｎ Ｃｏｒｐｏｒａｔｉｏｎ | アフィニティークロマトグラフィーのためのＦＣ−結合タンパク質、並びにＦｃ−結合タンパク質を含むアフィニティー分離マトリックスおよびその使用 |
| HUE070615T2 (hu) | 2016-10-17 | 2025-06-28 | Pfizer | Anti-EDB antitestek és antitest-gyógyszer konjugátumok |
| GB201621806D0 (en) | 2016-12-21 | 2017-02-01 | Philogen Spa | Immunocytokines with progressive activation mechanism |
| WO2019062877A1 (zh) * | 2017-09-30 | 2019-04-04 | 合肥立方制药股份有限公司 | 结合至纤维连接蛋白b结构域的蛋白 |
| EP3706804B1 (de) | 2017-11-07 | 2022-02-23 | Navigo Proteins GmbH | Fusionsproteine mit spezifität für ed-b und langer serumhalbwertszeit für diagnose oder behandlung von krebs |
| WO2019185792A1 (en) | 2018-03-29 | 2019-10-03 | Philogen S.P.A | Cancer treatment using immunoconjugates and immune check-point inhibitors |
| EP3660039A1 (de) | 2018-11-30 | 2020-06-03 | Philogen S.p.A. | Il2-immunkonjugate |
| WO2020070150A1 (en) | 2018-10-02 | 2020-04-09 | Philogen S.P.A | Il2 immunoconjugates |
| AU2019409572B2 (en) | 2018-12-18 | 2022-11-24 | Navigo Proteins Gmbh | Novel FOLR1 specific binding proteins for cancer diagnosis and treatment |
| MX2023015444A (es) | 2021-06-23 | 2024-04-29 | Cytune Pharma | Inmunocitocinas a base de interleucina-15. |
| BR112023027305A2 (pt) | 2021-06-23 | 2024-03-12 | Cytune Pharma | Variante de interleucina-15, conjugado, proteína de fusão, ácido nucleico, vetor, célula hospedeira e composição farmacêutica |
| JP7690131B2 (ja) | 2022-01-04 | 2025-06-09 | フィロジェン ソチエタ ペル アツィオーニ | Ｉｌ－１２を含むイムノサイトカインとキナーゼ阻害剤の組合せ |
| WO2024028258A1 (en) | 2022-08-01 | 2024-02-08 | Philochem Ag | Conjugates of psma-binding moieties with cytotoxic agents |
| AU2023332212A1 (en) | 2022-09-01 | 2025-04-10 | Philogen S.P.A. | Tnf alpha and interleukin-2 combination therapy for non-melanoma skin cancer |
| WO2024052333A1 (en) | 2022-09-06 | 2024-03-14 | Philochem Ag | Multivalent fibroblast activation protein ligands for targeted delivery applications |
| WO2025061801A1 (en) | 2023-09-19 | 2025-03-27 | Philochem Ag | Therapeutic combination of an anti-edb fibronectin domain antibody il2 or il12 fusion protein and a lutetium-177 radioconjugate |
| WO2026003203A1 (en) | 2024-06-27 | 2026-01-02 | Philogen S.P.A. | Combination of an immunocytokine comprising targeted il2 and a jak inhibitor |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9610967D0 (en) * | 1996-05-24 | 1996-07-31 | Cambridge Antibody Tech | Specific binding members,materials and methods |
-
1999
- 1999-05-10 TW TW088107648A patent/TWI259837B/zh active
- 1999-05-11 AU AU40398/99A patent/AU759207B2/en not_active Expired
- 1999-05-11 TR TR2000/03317T patent/TR200003317T2/xx unknown
- 1999-05-11 HU HU0102992A patent/HU225675B1/hu not_active IP Right Cessation
- 1999-05-11 WO PCT/EP1999/003210 patent/WO1999058570A2/en not_active Ceased
- 1999-05-11 EP EP99923571A patent/EP1084145B1/de not_active Expired - Lifetime
- 1999-05-11 EA EA200001169A patent/EA005685B1/ru not_active IP Right Cessation
- 1999-05-11 DE DE69926630T patent/DE69926630T2/de not_active Expired - Lifetime
- 1999-05-11 DK DK99923571T patent/DK1084145T3/da active
- 1999-05-11 CA CA2333833A patent/CA2333833C/en not_active Expired - Lifetime
- 1999-05-11 EE EEP200000802A patent/EE05435B1/xx not_active IP Right Cessation
- 1999-05-11 NZ NZ508600A patent/NZ508600A/xx unknown
- 1999-05-11 ES ES99923571T patent/ES2247802T3/es not_active Expired - Lifetime
- 1999-05-11 CN CNB998060526A patent/CN1250571C/zh not_active Expired - Lifetime
- 1999-05-11 IL IL13945299A patent/IL139452A0/xx unknown
- 1999-05-11 AT AT99923571T patent/ATE301676T1/de active
- 1999-05-11 BR BRPI9910394 patent/BRPI9910394B8/pt not_active IP Right Cessation
- 1999-05-11 CZ CZ20004216A patent/CZ300495B6/cs not_active IP Right Cessation
- 1999-05-11 JP JP2000548372A patent/JP2002514405A/ja active Pending
- 1999-05-11 SK SK1679-2000A patent/SK286822B6/sk not_active IP Right Cessation
- 1999-05-11 PL PL345845A patent/PL199353B1/pl not_active IP Right Cessation
-
2000
- 2000-11-10 NO NO20005694A patent/NO327732B1/no not_active IP Right Cessation
- 2000-11-10 IS IS5708A patent/IS2522B/is unknown
-
2006
- 2006-12-13 US US11/637,810 patent/US20070189963A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE301676T1 (de) | Antikörper gegen die ed-b domäne von fibronektin, solche antikörper enthaltende konjugate, und deren verwendung zur diagnose und therapie von angiogenese-assoziierten tumoren und krankheiten | |
| IL149171A0 (en) | Elisa for vegf | |
| DE69717664D1 (de) | Protein e25a, methoden zu dessen herstellung und anwendung | |
| ATE283289T1 (de) | Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheiten | |
| EP1590434A4 (de) | Mit bauchspeicheldrüsenkrebs assoziiertes antigen, antikörper dagegen sowie diagnose- und behandlungsverfahren | |
| ATE165395T1 (de) | Inhibitoren des tumorwachstums aus geweben, methoden ihrer herstellung und verwendungen | |
| MXPA02011656A (es) | Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos. | |
| KR910005862A (ko) | 신규 친수성 유도체, 진단 또는 치료시 그의 응용 그를 함유하는 진단 또는 치료용 키트 및 면역 시약 | |
| EE04298B1 (et) | Perfluoroalküülrühma sisaldavad metallikompleksidja nende kasutamine TMR-diagnostikas | |
| ATE483162T1 (de) | Trifunktionales reagenz zur verbindung von biomolekülen | |
| Gompels et al. | In vivo fluorescence imaging of E‐selectin: Quantitative detection of endothelial activation in a mouse model of arthritis | |
| SE8701905D0 (sv) | A method and a kit for the diagnosis of iga nephropathy | |
| DE69230970D1 (de) | Bicylclische, polyazamakrocyclocarbonsäure-komplexe, konjugate, herstellung und verwendung als kontraststoffe | |
| Cai et al. | Au/FeNiPO4‐Based Multiple Spectra Optoacoustic Tomography/CT Dual‐Mode Nanoprobe for Systemic Screening of Atherosclerotic Vulnerable Plaque | |
| DE10082504D2 (de) | Indikatorpeptid zur Diagnose und/oder Vorhersage von cardiovasculären und /oder endothelialen Erkrankungen, Antikörperzusammensetzung und immunoassay | |
| DE60014064D1 (de) | Einetenascin-c isoform als marker für neoplasmen | |
| BR112020024034A2 (pt) | composições e métodos para diagnóstico e tratamento de câncer | |
| BG105030A (en) | Antibodies against ed-b domain of fibronectin, conjugates containing them, and their application for diagnostics and treatment of tumours and morbid conditions related to angiogenesis | |
| DE69724761D1 (de) | Biotinylierter antikörper mit verminderter positiver nettoladung und toxin, medikament oder chelat | |
| Patel et al. | Adverse outcomes accompanying primary angioplasty (PTCA) for acute myocardial infarction (AMI)—Dangers of delay | |
| RU2000105525A (ru) | Способ оценки степени тяжести интоксикации у детей с гнойно-септическими заболеваниями | |
| BR9815776A (pt) | Anticorpos monoclonais anti-tag-72 humanizados com alta afinidade | |
| SI1084145T1 (sl) | Protitelesa za ED-B domeno fibronektina, konjugati, ki jih vsebujejo, in njihova uporaba za diagnozo in terapijo tumorjev in bolezni povezanih z angiogenezo | |
| FR2766927B1 (fr) | Methodes et kits pour le diagnostic de la maladie d'alzheimer | |
| EP1243653A3 (de) | E25a Protein, Methoden zur Herstellung und Verwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1084145 Country of ref document: EP |